Miltefosine
Miltefosine, an alkylphospholipid first developed as an anticancer drug, has been shown to have activity against Leis mania species and is a new oral drug for the treatment of visceral leishmaniasis.
Primary Characteristics
It is of Synthetic origin and belongs to Phospholipid.
It is also classified under Antiprotozal Agent .
Molecular Weight: 407.57 · Non-proprietary name: Miltefosine.
Pharmacokinetics
Elimination: plasma half-life is 6-8 days and 31 days.
Advertisement
Indications
Miltefosine is primarily indicated in conditions like Visceral leishmaniasis.
Miltefosine is also indicated for secondary conditions like Colorectal cancer, Metastatic breast cancer.
Contraindications
Miltefosine is contraindicated in conditions like Pregnancy.
Dosage
Miltefosine's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 2 mg/kg/day | 2 mg/kg/day | — | PO | Should be given for 28 days.The dose should be adjusted based on patients weight so that a dose of 4mg/kg per day is not exceeded. |
| 6 % | 6 % | — | Topical | Once or twice daily for skin metastasis. |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Miltefosine is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Hepatotoxicity, Nausea and vomiting.
Warnings / Precautions
Interference in Pathology
Miltefosine may interfere in the diagnosis of Increased in Serum Aminotransferase, Increased level of Blood urea nitrogen (BUN) concentrations, Increased in serum creatinin.
Available Brands
Click on a strength to view available brands.
Single Ingredient
Drug Classification
- 1.6.4.2 — Antileishmanial drugs
Manufacturers
Manufacturers of Miltefosine in Pakistan: